JPMorgan Chase & Co. Sells 7,138,646 Shares of Kenvue Inc. (NYSE:KVUE)

JPMorgan Chase & Co. lessened its stake in Kenvue Inc. (NYSE:KVUE) by 24.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 22,314,306 shares of the company’s stock after selling 7,138,646 shares during the quarter. JPMorgan Chase & Co. owned approximately 1.16% of Kenvue worth $476,410,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in KVUE. Alerus Financial NA lifted its position in Kenvue by 0.3% during the third quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock worth $4,426,000 after acquiring an additional 491 shares during the last quarter. Kiley Juergens Wealth Management LLC lifted its stake in Kenvue by 1.9% during the fourth quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock worth $579,000 after purchasing an additional 500 shares during the last quarter. Principle Wealth Partners LLC lifted its position in shares of Kenvue by 3.7% during the 4th quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company’s stock worth $303,000 after buying an additional 500 shares during the last quarter. White Pine Capital LLC lifted its holdings in shares of Kenvue by 1.0% in the fourth quarter. White Pine Capital LLC now owns 54,572 shares of the company’s stock worth $1,165,000 after acquiring an additional 542 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators boosted its position in Kenvue by 29.0% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company’s stock valued at $54,000 after buying an additional 568 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on KVUE shares. Royal Bank of Canada reissued a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. Citigroup dropped their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. UBS Group cut their price target on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a report on Friday, February 7th. Piper Sandler increased their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. Finally, Evercore ISI assumed coverage on shares of Kenvue in a research report on Monday, March 24th. They issued an “in-line” rating and a $25.00 price target for the company. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $24.00.

Kenvue Trading Up 1.0 %

NYSE KVUE opened at $23.74 on Friday. The business’s fifty day moving average is $22.32 and its 200-day moving average is $22.45. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The stock has a market capitalization of $45.36 billion, a price-to-earnings ratio of 44.78, a PEG ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities research analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were issued a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.45%. The ex-dividend date was Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.